心血管磁共振成像在心脏淀粉样变性中的作用：一篇叙述性综述。
Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review.
作者信息
Maggialetti Nicola, Torrente Andrea, Lorusso Giovanni, Villanova Ilaria, Ficco Michele, Gravina Matteo, Ferrari Cristina, Giordano Luca, Granata Vincenza, Rubini Dino, Lucarelli Nicola Maria, Stabile Ianora Amato Antonio, Scardapane Arnaldo
机构信息
Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
U.O.C. Radiologia, P.O. San Paolo, ASL Bari, 70123 Bari, Italy.
出版信息
J Pers Med. 2024 Apr 11;14(4):407. doi: 10.3390/jpm14040407.
Abstract
Amyloidosis is a rare infiltrative condition resulting from the extracellular accumulation of amyloid fibrils at the cardiac level. It can be an acquired condition or due to genetic mutations. With the progression of imaging technologies, a non-invasive diagnosis was proposed. In this study, we discuss the role of CMR in cardiac amyloidosis, focusing on the two most common subtypes (AL and ATTR), waiting for evidence-based guidelines to be published.
摘要
淀粉样变性是一种罕见的浸润性疾病，由心脏水平的淀粉样原纤维细胞外积聚引起。它可以是后天性疾病，也可能是基因突变所致。随着成像技术的发展，人们提出了非侵入性诊断方法。在本研究中，我们讨论了心脏磁共振成像（CMR）在心脏淀粉样变性中的作用，重点关注两种最常见的亚型（AL和ATTR），同时等待基于证据的指南发布。
相似文献
1
Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review.
J Pers Med. 2024 Apr 11;14(4):407. doi: 10.3390/jpm14040407.
2
Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
Clin Res Cardiol. 2021 Apr;110(4):555-568. doi: 10.1007/s00392-020-01771-1. Epub 2020 Nov 10.
3
Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis.
JACC Cardiovasc Imaging. 2020 Jun;13(6):1299-1310. doi: 10.1016/j.jcmg.2020.03.010.
4
Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
Curr Probl Cardiol. 2023 Apr;48(4):101573. doi: 10.1016/j.cpcardiol.2022.101573. Epub 2022 Dec 28.
5
The Role of T2 Mapping in Cardiac Amyloidosis.
Diagnostics (Basel). 2024 May 18;14(10):1048. doi: 10.3390/diagnostics14101048.
6
Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
Int J Cardiol. 2024 May 15;403:131892. doi: 10.1016/j.ijcard.2024.131892. Epub 2024 Feb 19.
7
Diagnosis of Cardiac Involvement in Amyloid A Amyloidosis by Cardiovascular Magnetic Resonance Imaging.
Front Cardiovasc Med. 2021 Sep 27;8:757642. doi: 10.3389/fcvm.2021.757642. eCollection 2021.
8
The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
Front Cardiovasc Med. 2022 Oct 18;9:1017097. doi: 10.3389/fcvm.2022.1017097. eCollection 2022.
9
The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.
J Cardiovasc Magn Reson. 2018 Jan 3;20(1):2. doi: 10.1186/s12968-017-0419-6.
10
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
Circulation. 2015 Oct 20;132(16):1570-9. doi: 10.1161/CIRCULATIONAHA.115.016567. Epub 2015 Sep 11.
引用本文的文献
1
The Role of Artificial Intelligence in Cardiac Amyloidosis: A Focus on Diagnosis and Clinical Application.
J Cardiovasc Dev Dis. 2025 Jun 11;12(6):221. doi: 10.3390/jcdd12060221.
2
Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.
Cardiol Res. 2024 Aug;15(4):211-222. doi: 10.14740/cr1664. Epub 2024 Jul 18.
本文引用的文献
1
Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: a systematic review with meta-analysis.
Eur Heart J Open. 2023 Sep 22;3(5):oead092. doi: 10.1093/ehjopen/oead092. eCollection 2023 Sep.
2
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Eur J Heart Fail. 2022 Dec;24(12):2342-2351. doi: 10.1002/ejhf.2532. Epub 2022 May 16.
3
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2022 Apr 5;79(13):1288-1303. doi: 10.1016/j.jacc.2022.01.036.
4
Cardiac Amyloidosis: A Review of Current Imaging Techniques.
Front Cardiovasc Med. 2021 Dec 10;8:751293. doi: 10.3389/fcvm.2021.751293. eCollection 2021.
5
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
6
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur J Heart Fail. 2021 Apr;23(4):512-526. doi: 10.1002/ejhf.2140. Epub 2021 Apr 7.
7
Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).
Clin Res Cardiol. 2021 Apr;110(4):479-506. doi: 10.1007/s00392-020-01799-3. Epub 2021 Jan 18.
8
Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
Clin Res Cardiol. 2021 Apr;110(4):555-568. doi: 10.1007/s00392-020-01771-1. Epub 2020 Nov 10.
9
Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study.
Europace. 2020 Dec 23;22(12):1864-1872. doi: 10.1093/europace/euaa171.
10
JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.
Circ J. 2020 Aug 25;84(9):1610-1671. doi: 10.1253/circj.CJ-20-0110. Epub 2020 Aug 21.
Zotero 插件